Repertoire Immune Medicines inks $189m Series B
Repertoire Immune Medicines, a clinical-stage biotech company, has secured $189 million in Series B financing.
Repertoire Immune Medicines, a clinical-stage biotech company, has secured $189 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination